



University of Dundee

O-GlcNAcase Fragment Discovery with Fluorescence Polarimetry

Borodkin, Vladimir S.; Rafie, Karim; Selvan, Nithya; Aristotelous, Tonia; Navratilova, Iva; Ferenbach, Andrew T.

Published in:
ACS Chemical Biology

DOI:
[10.1021/acscchembio.8b00183](https://doi.org/10.1021/acscchembio.8b00183)

Publication date:
2018

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Borodkin, V. S., Rafie, K., Selvan, N., Aristotelous, T., Navratilova, I., Ferenbach, A. T., & Van Aalten, D. M. F. (2018). O-GlcNAcase Fragment Discovery with Fluorescence Polarimetry. *ACS Chemical Biology*, 13(5), 1353-1360. <https://doi.org/10.1021/acscchembio.8b00183>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

O-GlcNAcase fragment discovery with fluorescence polarimetry

Journal:	<i>ACS Chemical Biology</i>
Manuscript ID	cb-2018-00183u.R2
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	BORODKIN, Vladimir; University of Dundee, Gene Regulation and Expression Rafie, Karim; University of Dundee, Centre for Gene Regulation and Expression, School of Life Sciences Selvan, Nithya; University of Georgia Complex Carbohydrate Research Center Aristotelous, Tonia; University of Dundee College of Life Sciences Navratilova, Iva; University of Dundee, College of Life Sciences Ferenbach, Andrew; University of Dundee, Centre for Gene Regulation and Expression, School of Life Sciences van Aalten, Daan; University of Dundee, Centre for Gene Regulation and Expression, School of Life Sciences

SCHOLARONE™
Manuscripts

This is the accepted manuscript version of the following article:

Borodkin, VS, Rafie, K, Selvan, N, Aristotelous, T, Navratilova, I, Ferenbach, AT & Van Aalten, DMF 2018, '**O-GlcNAcase Fragment Discovery with Fluorescence Polarimetry**' ACS Chemical Biology, vol 13, no. 5, pp. 1353-1360. DOI: 10.1021/acscchembio.8b00183

O-GlcNAcase fragment discovery with fluorescence polarimetry

Vladimir S. Borodkin^{1,*#}, Karim Rafie^{1#}, Nithya Selvan^{1,3#}, Tonia Aristotelous², Iva Navratilova²,
Andrew T. Ferenbach¹ and Daan M. F. van Aalten^{1*}


¹*Centre for Gene Regulation and Expression and* ²*Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, United Kingdom.* ³*Present address: Complex Carbohydrate Research Center, University of Georgia, Athens, GA, United States.*

**To whom correspondence should be addressed at vsborodkin@dundee.ac.uk or dmfvanaalten@dundee.ac.uk*

#These authors contributed equally

Abstract

The attachment of the sugar D-N-acetylglucosamine (GlcNAc) with to specific serine and threonine residues on proteins is referred to as protein O-GlcNAcylation. O-GlcNAc transferase (OGT) is the enzyme responsible for carrying out the modification while O-GlcNAcase (OGA) reverses it. Protein O-GlcNAcylation has been implicated in a wide range of cellular processes including transcription, proteostasis and stress response. Dysregulation of O-GlcNAc has been linked to diabetes, cancer, neurodegenerative and cardiovascular disease. OGA has been proposed to be a drug target for the treatment of Alzheimer's and cardiovascular disease given that increased O-GlcNAc levels appear to exert a protective effect. The search for specific, potent and drug-like OGA inhibitors with bioavailability in the brain is therefore a field of active research, requiring orthogonal high-throughput assay platforms. Here we describe the synthesis of a novel probe for use in a fluorescence polarization based assay for the discovery of inhibitors of OGA. We show that the probe is suitable for use with both human OGA, as well as the orthologous bacterial counterpart from *Clostridium perfringens*, CpOGA, and the lysosomal hexosaminidases HexA/B. We structurally characterize CpOGA in complex with a ligand identified from a fragment library screen using this assay. The versatile synthesis procedure could be adapted for making fluorescent probes for the assay of other glycoside hydrolases.



Introduction

Protein O-GlcNAcylation is the dynamic and reversible modification of specific serine and threonine side chains on multitude of nucleocytoplasmic and mitochondrial proteins with a single β -N-acetylglucosamine residue¹. The attachment of the sugar is catalyzed by the enzyme O-GlcNAc transferase (OGT) and its removal by O-GlcNAcase (OGA). Both OGT and OGA are essential enzymes in mice, with their loss resulting in lethality²⁻⁴. Protein O-GlcNAcylation is involved in various cellular processes including transcription⁵⁻⁸, protein stability/degradation⁹, and stress response¹⁰⁻¹²; in most these processes, however, the exact role of O-GlcNAcylation is yet to be deciphered. Dysregulation of O-GlcNAc cycling, associated with malfunctions in the production and activity of the processing enzymes, is a feature of pathological conditions such as diabetes, cancer, Alzheimer's disease and cardiovascular disease^{1, 9, 13-15}.

The structural characterization of bacterial OGAs and more recently human OGA gave insights into the binding mode of O-GlcNAc proteins¹⁶⁻²⁰. Schimpl *et al.* showed that glycosylated substrate peptides bind in a conserved groove in a similar conformation and orientation, adopting a "V"-shaped conformation with the residue side chains pointing away from the active site, explaining how a single enzyme can recognize > 1000 different substrates¹⁶. Inspection of the structures revealed that the peptide backbone forms interactions with OGA, in the -4 through the +3 position surrounding the O-GlcNAc site¹⁶. Additional hydrophobic interactions are formed by residues in the -1 and -2 position and a surface exposed Tyr¹⁸⁹ in CpOGA, which is conserved in the human OGA (Tyr⁶⁹)^{16, 17}. Studies revealed that mutation of Tyr69 in human OGA leads to a significant reduction in catalytic activity on the substrate analogue 4-methylumbelliferyl- β -D-N-acetylglucosaminide (4MU-GlcNAc)¹⁷.

Structural studies of human OGT²¹⁻²³ and bacterial orthologues of OGA^{24, 25} have allowed the development of inhibitors²⁶⁻³³ to study the function of these enzymes at the molecular and cellular level. In the case of OGA, potent, cell penetrant inhibitors exist²⁹⁻³³, and have been used for the identification of OGA as a potential drug target for the treatment of Alzheimer's disease (AD) and cardiovascular disease³⁴⁻³⁶. Hyperphosphorylation of the protein tau resulting in the formation of

neurofibrillary tangles (NFTs) in AD leading to neuronal loss can be slowed by increasing O-GlcNAcylation, which stabilizes tau, preventing its aggregation³⁴. This study was performed using mice fed with the OGA inhibitor Thiamet G³⁰. A chemically related molecule NButGT²⁹ was shown to prevent the accumulation of the protein amyloid β , neuroinflammation and memory loss in another mouse model of AD³⁵. With respect to cardiovascular disease, inhibition of OGA using NAG thiazolines and NButGT was shown to be protective and attenuate tissue necrosis after ischaemia/reperfusion injury^{36, 37}. Furthermore, genetic studies have suggested that deletion of *oga* is perinatally lethal although it is not yet clear whether this essentiality is limited to early development^{3, 4}. While potent and selective, the existing inhibitors of OGA possess a carbohydrate scaffold, which has poor drug-like properties with respect to Lipinski's rules. Achieving therapeutic concentrations of these molecules *in vivo* requires the administration of large quantities of the drugs. Molecules with improved stability, pharmacology and penetrability of the blood-brain barrier are desired and the search for these is the subject of ongoing research, exemplified by recent studies describing the use of click chemistry for the rapid generation of potential OGA inhibitor libraries³⁸ and the use of existing chemical libraries for the discovery of new drug-like inhibitor scaffolds³⁹.

Fluorescence polarization (FP) is one of many techniques used for the analysis of ligand-protein interactions. The FP technique offers advantages over methods such as surface plasmon resonance (SPR) and biolayer interferometry (BLI) for the measurement of binding affinities of proteins to ligands⁴⁰. It is robust, the quantities of protein/ligands required for an FP assay are comparatively low and neither proteins nor ligands require to be immobilized to a surface. This makes the FP assay completely solution-based and minimizes skewing of binding equilibrium, which could occur by immobilizing a protein, as this may impose constraints on structural changes that could occur upon ligand binding^{40, 41}. Also, as a solution based technique, an FP assay is more amenable to high throughput formats. While the OGA activity assay based on the hydrolysis of the fluorescent substrate 4MU-GlcNAc provides a method for the discovery of OGA inhibitors^{24, 42}, the measurement of inhibition constants for potent inhibitors requires long incubations periods (e.g. ~7 h for *CpOGA* and

1 GlcNAcstatin C)³². An advantage of an FP based OGA assay is direct measurement of binding rather
2 than loss of activity, reducing assay length. The main limiting factor in the development of an FP
3 assay is the requirement for a tailor-made fluorescent ligand with high affinity to the protein/receptor
4
5 under study, which is what we report here.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results and Discussion

Previously, we established a robust synthetic approach to a family of highly potent and selective OGA inhibitors, built on 8-alkylamido 2-phenethyl substituted bicyclic sugar-imidazole scaffold (GlcNAcstatins)⁴³. Here we disclose the synthesis of a fluorescently tagged derivative of the potent OGA inhibitor GlcNAcstatin B **1** created by the replacement of the 2-phenethyl group of the parent molecule with aminopropyl spacer labeled with FITC (hereafter referred to as GlcNAcstatin BF **2** (Fig. 1)).





Figure 1. Structures of GlcNAcstatin B (1) and GlcNAcstatin BF (2)

We also report a novel FP displacement assay using GlcNAcstatin BF as a fluorescent tracer to measure the binding affinities of existing inhibitors to the bacterial OGA from *Clostridium perfringens*, CpOGA, as well as human OGA (hOGA).

We initially devised a concise synthetic scheme to access GlcNAcstatin BF **2** (Scheme 1). We scheduled the chemoselective installation of a fluorescent tag onto the derivative **3** bearing the requisite aminopropyl handle that supports the final steps in synthesis of the target compound. To reach **3** we devised a novel synthetic approach for the construction of the 8-alkylamido 2-substituted sugar-imidazole **4** by reversing the order in which the corresponding substituents would be introduced into the target molecule as compared to the published approach⁴³.




Scheme 1. Retrosynthetic analysis of GlcNAcstatin BF

Accordingly, we planned to transform the known key 2-iodo-mannose-imidazole **6** into GlcNAc-imidazole derivative **5**, which in turn was to be coupled with N-Boc propargyl amine in a Sonogashira reaction giving the intermediate **4**. Although this previously unexplored reverse sequence lacks the flexibility of the previously published approach⁴³, it sufficed for the case where synthesis of the sole N-acetyl derivative was required.

Previously, the intermediate **6** was prepared by regioselective mono-deiodination of the diiodo-derivative **6a**, which in turn was the product of a challenging bis-iodination (8 eq of NIS, 85 °C, 36 h) of the bicyclic sugar-imidazole **6b**. The latter process was found to be unsuitable for upscaling, resulting in formation of varying amounts of the triply iodinated (*ortho* position in the *p*-methoxybenzyl (PMB) group) product, depending on the quality of NIS used. As an alternative route to intermediate

6, we decided to reinvestigate the cyclization of the linear 4,5-diiodimidazole **7**, which was previously found to be inert in a triflic anhydride mediated process⁴³ (Scheme 2).

Scheme 2^a

^a Reagents and conditions: (a) Tf_2O , $\text{C}_2\text{H}_4\text{Cl}_2$, 65°C ; (b) PPh_3 , DIAD, THF, 65°C , 1 h, 85%; (c) EtMgBr , THF, 0°C , 1 h, 89%; (d) TFA- H_2O 1:9, DCM, 1 h, RT, 85%; (e) DPPA, DBU, Tol, 90°C , 1 h, 95%; (f) PPh_3 , THF- H_2O , 65°C , 3 h, then Ac_2O , DIPEA, 16 RT, 85%; (g) $\text{HCCCH}_2\text{NHBoc}$; $\text{Pd}(\text{PPh}_3)_4$, CuI, Et_3N , DMF, 85°C , 16 h, 53%; (h) H_2 , Pd/C, MeOH, 2 h, RT; (i) HCl:TFE 1:50, 50°C , 2 h followed by FITC, DIPEA, DMF, RT, 1 h, 65% over two steps.

We assumed that the decreased pK_a of the imidazole moiety in **7** would facilitate intramolecular reactivity under Mitsunobu N-alkylation conditions, giving the bicyclic sugar imidazole **6a** directly. The intermolecular Mitsunobu N-alkylation reaction of imidazoles bearing electron-withdrawing substituents with different alcohols, including secondary, has several precedents in the literature^{44, 45}. Furthermore, Mitsunobu type cyclization of structurally similar sugar-derived 1,4-diols was consistently used for the synthesis of C-nucleosides including C2-imidazole and benzimidazole

1 derivatives^{46, 47}. In our hands, reaction of the linear precursor **7** under standard Mitsunobu conditions
2 (PPh₃, DIAD, 65 °C) resulted in formation of the expected known bicyclic product **6a** in excellent yield
3 (Scheme 2). The reaction was shown to be equally applicable to multi-gram scale preparations.
4
5 Taken together, the novel intramolecular Mitsunobu N-alkylation of **7** in conjunction with the proven
6
7 highly efficient regioselective mono-deiodination of **6a** represents a streamlined (and more economic)
8
9 access to the key 2-iodoimidazole **6** that supersedes the triflic anhydride mediated cyclization/bis-
10
11 iodination sequence of the former approach⁴³.
12
13
14
15

16 We have previously documented the hydrolytic stability of the BDA group in the GlcNAc-imidazoles
17
18 ⁴³. Now we reveal that this phenomenon also works for neutral glycoimidazoles to introduce useful
19
20 orthogonality towards acidolysis between PMB and BDA groups. Indeed, using the standard
21
22 conditions for the deprotection of the PMB group (aqueous 90% TFA in DCM⁴⁸) we were able to
23
24 selectively remove the 8-O PMB group in **6** without affecting the DBA⁴⁹ and (less surprisingly) the
25
26 TIPS groups to obtain the monohydroxylic compound **8** in 85 % yield (Scheme 2). This
27
28 counterintuitive deprotection protocol offers a simplified alternative to the DDQ-mediated PMB
29
30 removal of the original approach⁴³.
31
32
33
34

35 Using **8** as the substrate, the stereoselective azide introduction with inversion of configuration
36
37 proceeded smoothly according to the established protocol to give *gluco*-imidazole **9** in a nearly
38
39 quantitative yield. Next, a one-pot stepwise Staudinger reduction/acetylation sequence applied to **9**
40
41 gave the crucial 2-iodo-GlcNAc-imidazole **5** in high yield. The Sonogashira coupling of derivative **5**
42
43 with N-Boc propargyl amine resulted in a fair yield (53%) of the desired advanced intermediate **4**.
44
45 Overall, we have successfully implemented a novel synthetic approach for the construction of 8-
46
47 alkylamido-2 substituted sugar–imidazoles. This approach produces comparable efficiency to the
48
49 original one on all the separate steps but Sonogashira coupling, where somewhat diminished yield
50
51 was recorded.
52
53
54

55 The concluding transformation of **4** into the targeted fluorescent tracer **2** was initiated with
56
57 hydrogenation of the triple bond to give the C-2 aminopropyl equipped derivative **10**. The pivotal one-
58
59
60

1 pot global removal of the protecting groups in **10** was efficiently achieved with 12 M HCl in
2 trifluoroethanol (1:50) at 55 °C for 2 h to give the fully deprotected compound **3**^{50, 51} which was
3 (without purification) treated with a slight excess of FITC in DMF to furnish the fluorescently tagged
4 product **2** (Scheme 2). The reaction mixture was directly purified by reverse phase flash
5 chromatography on a C18 column and the product was re-purified to homogeneity by HPLC to afford
6 the desired GlcNAcstatin BF in 65% yield over the three-step sequence.
7
8
9
10
11
12

13
14 We next wanted to assess the use of GlcNAcstatin BF with *Cp*OGA and hOGA in an FP assay.
15
16 GlcNAcstatin BF bound to *Cp*OGA with a K_d of 0.5 ± 0.2 nM (Fig. 2a) and to hOGA with a K_d of $143 \pm$
17 29 nM (Fig. 2b). We then used GlcNAcstatin BF in displacement assays to measure the K_d of the
18 inhibitors GlcNAcstatin B and GlcNAcstatin G. Consistent with previous reports^{32, 33}, GlcNAcstatin B
19 was a better binder of *Cp*OGA with a K_i of 6.6 nM versus 16.3 nM for GlcNAcstatin G (Fig. 2c). For
20 hOGA, however, the K_i obtained for GlcNAcstatin B was 23.2 nM and for GlcNAcstatin G, it was 21.4
21 nM (Fig. 2d). The absolute K_i values obtained for these inhibitors are not consistent with previously
22 reported K_i values obtained using the 4MU-NAG based activity assay^{32, 33}. In addition to the variability
23 expected from using different methods, this could be due to the differences in the assay buffer and
24 pH used or the different N-terminal truncation of the construct used in this study. Dorfmueller *et al.*,
25 used the McIlvaine buffer system at pH 5.7/7.3^{32, 33}, while here we use Tris buffered saline (TBS) at
26 pH 7.5. The K_i values obtained with the FP assay for the binding of *Cp*OGA to GlcNAcstatin G and
27 another potent OGA inhibitor Thiamet G³⁰ are consistent with those obtained using surface plasmon
28 resonance (SPR) performed using the same assay buffer (Supplementary Fig. S1); the binding
29 affinity of hOGA for Thiamet G using the FP assay is shown in Supplementary Fig. S2. These proof-
30 of-concept experiments establish the fluorescence polarization displacement assay using
31 GlcNAcstatin BF as a convenient method for evaluating affinity of OGA inhibitors.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Binding affinity of GlcNAcstatin BF and two inhibitors of the GlcNAcstatin family to CpOGA and hOGA.

FP assay showing the binding of GlcNAcstatin BF to **a)** CpOGA and **b)** hOGA. Binding was measured by incubating for 10 min (CpOGA) and 180 min (hOGA) at a fixed concentration of labeled probe ($[GBF_{CpOGA}] = 0.5$ nM, $[GBF_{hOGA}] = 50$ nM) with varying concentrations of enzyme. Data points were fitted to a one-site specific-binding equation using Prism (GraphPad). Experiments were performed in triplicate and error bars represent standard error of the mean. Dose-response curves from the fluorescence polarization assay showing the displacement from **c)** CpOGA or **d)** hOGA of a fixed concentration of fluorescent probe by increasing concentrations of GlcNAcstatin B or GlcNAcstatin G. Highest amount of probe bound to enzymes in the absence of inhibitors was set as 100%. Data points were fitted to a four-parameter equation for dose-dependent inhibition using Prism (GraphPad). Experiments were performed in triplicate and error bars represent standard error of the mean. A summary including Hill Slopes can be found in Supplementary Material Table 1.

To expand the applicability of the suggested assay system for the high-throughput screening of custom compound libraries, we decided to evaluate the Maybridge Ro3 1000 fragment library towards CpOGA as a target. This library consists of fragments that adhere to the 'rule of three' (Ro3) (molecular weight ≤ 300 Da, no more than 3 hydrogen bond donors/acceptors, $cLogP \leq 3$). The

1 screen was performed under experimental conditions matching those used in the displacement of
2 GBF by Thiamet G and GlcNAcstatin G (Supplementary material Fig. S3).
3
4
5

6
7 The quality of both screens was estimated by calculating Z' value across the controls on a given
8 plate¹, which is a measure of the statistical effect size and therefore the suitability of a high-
9 throughput assay system. In our hands, we consistently saw Z' values for each plate between 0.73
10 – 0.84 with respect to the standard readings, with a Z' value of 0.66 for readings across all four
11 plates. We chose to identify compounds as hits if they reduced the maximum polarization by $\geq 40\%$,
12 resulting in a list of 15 initial hits. Subsequently, the initial hits were advanced into the second round
13 of testing, in which we determined the K_i values by measuring the displacement of GlcNAcstatin BF in
14 a dose-dependent manner. Out of the 15 initial hits (F1-F15, Supplementary Material Fig. 3,
15 Supplementary Material Table 2), 8 were confirmed as binders of CpOGA with apparent K_i values
16 between 9 – 150 μM .
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Binding of a fragment hit to Tyr¹⁸⁹ and Asp⁴⁰¹ blocks GlcNAcstatin BF and substrate binding**

34 To further validate the fragments identified as binders in the HTS screen, we performed
35 macromolecular x-ray crystallography to identify the binding mode of a subset of these hits. We
36 managed to solve the structure of CpOGA in complex with 5-(trifluoromethyl)-2,3-dihydro-1*H*-1,4-
37 diazepine (Fragment F8 hereafter referred to as 5TFD, apparent $K_i = 146 \mu\text{M}$, Fig. 3A). We collected
38 synchrotron diffraction data to 2.6 Å (Supplementary material Table 3) allowing structure solution by
39 molecular replacement and subsequent refinement (final $R_{\text{work}}/R_{\text{free}} = 0.17/0.22$). There was
40 continuous $|F_o| - |F_c|$ electron density for the fragment (Fig. 3B). 5TFD binds proximal to the active site
41 pocket, forming hydrophobic stacking interactions with Tyr¹⁸⁹ (Fig 3B). Additionally, the secondary
42 amine of 5TFD forms a hydrogen bond with the backbone carbonyl oxygen of Asp⁴⁰¹ (Fig. 3B). Tyr¹⁸⁹
43 has been previously identified to be important for substrate binding, forming hydrophobic interactions
44 with the substrate peptide backbones¹⁶. When compared to a structure of CpOGA in complex with
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

GlcNAcstatin F (Fig. 3 C, PDBID: 2XPK⁵²), a nM inhibitor of CpOGA designed to mimic the reaction intermediate, 5TFD forms different interactions. However, taking into account the longer linker and presence of the fluorescein group present in GlcNAcstatin BF it is possible for 5TFD to form a steric barrier for proper GBF binding. Thus, the 5TFD fragment bound to Tyr¹⁸⁹ and Asp⁴⁰¹, is able to block binding of GlcNAcstatin BF and glycopeptide substrates.




Figure 3. Binding affinity of 5TFD and binding mode of 5TFD and GlcNAcstatin C to CpOGA. a) Dose-response curves from the fluorescence polarization assay showing the displacement from CpOGA of a fixed concentration of fluorescent probe by increasing concentrations of 5TFD. Highest amount of probe bound to enzymes in the absence of inhibitors was set as 100% and a fictive concentration of 10 M set as 0%. Data points were fitted to a four-parameter equation for dose-dependent inhibition using Prism (GraphPad). Experiments were performed in triplicate and error bars represent standard error of the mean. A summary including Hill Slopes can be found in Supplementary Material Table 2. Structure of CpOGA in complex with b) 5TFD and c) GlcNAcstatin F (PDBID 2XPK⁵²). The protein is shown as grey cartoon with active site residues shown as sticks. Ligands are shown as green sticks. Hydrogen bonds between ligands and active site residues are shown as dashed black lines. The unbiased $|F_o| - |F_c|$ electron density map for 5TFD is shown as blue mesh contoured at 2σ .

GlcNAcstatin BF may not only be useful to measure the binding of ligands to OGA, but also to enzymes of related glycoside hydrolase families such as GH20, to which human HexA/B belong. This is because GlcNAcstatin B itself, while potent, is not a selective inhibitor of OGA³² and also targets HexA/HexB. We were able to determine an apparent K_d of $\sim 4\ \mu\text{M}$ (Supplementary Material Figure 4) for GlcNAcstatin BF to HexA/B isolated from bovine kidneys. HexA/HexB have recently been

1 explored as targets for enzyme enhancement therapy to treat the lysosomal storage diseases Tay-
2 Sachs and Sandhoff disease⁵³ and an FP based assay offers an alternative to activity assays for the
3 screening of fragments/compounds that bind to these proteins.
4
5
6
7
8

9 Here we have reported the design and synthesis of the novel fluorescent probe GlcNAcstatin BF to
10 support miniaturized OGA high-throughput assays. To synthesize the target compound we
11 established a novel synthetic approach for the construction of the 8-N alkylamide 2-substituted sugar-
12 imidazoles by reversing the order of the introduction of the respective substituents into the key
13 intermediate as compared to the original approach. As part of the study, we also developed a novel
14 method for the synthesis of bicyclic sugar-imidazoles via intramolecular Mitsunobu N-alkylation of 4,5-
15 diiodoimidazoles to supersede the challenging sequence of the former approach. We successfully
16 applied a simplified counterintuitive acid hydrolysis procedure for the removal of the PMB protection
17 in the presence of cyclic BDA, the product of the unique substrate-induced orthogonality between
18 PMB and DBA groups. Notably, we established a fast and high yielding procedure for the global
19 deprotection of the penultimate synthetic intermediate including removal of the notoriously stable BDA
20 group that constitutes an expedient alternative to the TFA based method previously used for the
21 GlcNAcstatin synthesis. We have shown that GlcNAcstatin BF is suitable for use in fluorescence
22 polarization assays to measure the binding affinity of OGA inhibitors and identify novel binders from a
23 high-throughput screen of a 1000-member fragment library. Finally, we solved the structure of
24 CpOGA in complex with a binder identified in the screen and were able to show that it binds to
25 Tyr189, an important residue for substrate binding.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Crystallography and structure solution

*Cp*OGA was concentrated to 40 mg mL⁻¹ in 25 mM Tris-HCl pH 8.0, 20 mM NaCl, 0.5 mM TCEP. Sitting-drop vapor diffusion crystallization experiments were performed by mixing drops in a 1:1 ratio of *Cp*OGA and 0.175 M CdSO₄, 0.1 M sodium acetate pH 7.5 and needle shaped crystals appeared after 3-4 days. A 5FTD fragment complex was achieved by transferring crystals into a drop containing 10 mM 5FTD in 0.175 M CdSO₄, 0.1 M sodium acetate pH 7.5, 1% DMSO for 4 h prior to cryoprotection with 20% glycerol in mother liquor saturated with 5TFD. Diffraction data was collected at the European Synchrotron Radiation Facility (ESRF) on beamline ID30A-3, were processed with XDS⁵⁴ and scaled to 2.6 Å using aimless⁵⁵. 5% of total reflections were set aside as an R_{free} test set. Crystals belonged to space group P61 with one molecule per asymmetric unit, a solvent content of 72% and a Matthews coefficient of 4.5. The structures were solved with MOLREP⁵⁶, using chain A of PDB 2YDS¹⁶ as a search model. The structure was fully refined using iterative cycles of Refmac5⁵⁷ and COOT⁵⁸. Ligand topology was generated using PRODRG⁵⁹. X-ray diffraction data collection and structure refinement statistics can be found in the supplementary material (Supplementary Material Table 3).

Fluorescence Polarization

Experiments were performed in PerkinElmer, black, 384-well plates and millipolarization units measured using a Pherastar FS plate reader (BMG LABTECH) at excitation and emission wavelengths of 485 nm and 520 nm, respectively. For determination of the equilibrium dissociation constant (K_d) of *Cp*OGA and hOGA for GlcNAcstatin BF, 0.5 nM/50 nM of the probe was incubated with a range of concentrations of protein in 25 µL/ 30µL total reaction volume containing 1 x TBS (25 mM Tris, 150 mM NaCl, pH 7.5) buffer and a final concentration of 1-2% DMSO. Reactions were allowed to stand at room temperature for 10 min for *Cp*OGA and 3 h for hOGA, after which

1 polarization was measured (equilibrium was reached within these time points). Readings were
2 corrected for background emissions from reactions without enzyme and the K_d was determined by
3 fitting a non-linear regression curve with Prism (GraphPad). To avoid receptor depletion, reaction
4 mixtures for competition binding experiments contained 1 nM fluorescent probe for CpOGA and 50
5 nM for hOGA, 7 nM of CpOGA/250 nM hOGA (receptor) and a range of concentrations of inhibitors in
6 the aforementioned reaction conditions. The largest amount of fluorescent probe bound to the
7 receptors in the absence of competing ligands was set as 100%. IC_{50} values were determined by
8 fitting dose-response curves with Prism (GraphPad) and converted to K_d as outlined elsewhere⁶⁰. All
9 experiments were performed in triplicate.
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **High-throughput screen of the Maybridge Ro3 1000 fragment library**

24
25
26 The Maybridge Ro3 1000 fragment library (Maybridge) screen was performed in black, 384-well
27 plates (PerkinElmer). Displacement of GlcNAcstatin BF was measured by adding 25 μ L of 7 nM
28 CpOGA and 1 nM GlcNAcstatin BF in assay buffer (0.1 M Tris-HCl pH 7.4, 150 mM NaCl, 1% DMSO)
29 to assay plates containing 50 nL of a 0.1 M fragment solutions in DMSO, resulting in a final assay
30 concentration of 200 μ M. The plates were allowed to stand for 10 minutes in the dark before reading
31 polarization on a Pherastar FS plate reader (BMG Labtech) at excitation and emission wavelengths of
32 485 nm and 520 nm, respectively. Readings were corrected for background polarization from
33 reactions containing only 1 nM GlcNAcstatin BF in assay buffer and normalised to readings
34 containing 1% DMSO. Fragments displacing GlcNAcstatin BF by $\geq 40\%$ were classified as hits and
35 were advanced for K_i value determination. Competition binding experiments were conducted under
36 the same assay conditions in 0.1 M Tris-HCl pH 7.4, 150 mM NaCl, 2% DMSO and varying
37 concentrations of fragments. K_i values were calculated as described above.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accession codes

The atomic coordinates and structure factors have been deposited in the Protein Data Bank⁶¹ under the accession code 5OXD.

Supporting information

The Supporting Information, including synthetic procedures and spectral data for all new compounds, methods, figures and tables as well as the compound characterization checklist and the validation report of the deposited structure are available free of charge via the Internet.

Acknowledgements

We thank the European Synchrotron Radiation Facility (ESRF) for beam time on ID30A-3 and assistance. This work was funded by a Wellcome Trust Senior Research Fellowship (WT087590MA) to DMFvA. We would like to thank Dr. M. Schimpl for purifying hOGA.

Author Contributions

The study was conceived by VSB, NS and DMFvA. Synthesis was performed by VSB; protein purification, protein biotinylation and FP assays were performed by NS; KR performed HTS, FP and hit-validation assays and structural biology; cloning was performed by ATF and SPR was performed by TA and IHN. Data were analysed by all authors. The manuscript was written by VSB, NS, KR and DMFvA.


References

- [1] Hart, G. W., Slawson, C., Ramirez-Correa, G., and Lagerlof, O. (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease, *Annu. Rev. Biochem.* **80**, 825-858.
- [2] Shafi, R., Iyer, S. P., Ellies, L. G., O'Donnell, N., Marek, K. W., Chui, D., Hart, G. W., and Marth, J. D. (2000) The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny, *Proc. Natl. Acad. Sci. U. S. A.* **97**, 5735-5739.
- [3] Yang, Y. R., Song, M., Lee, H., Jeon, Y., Choi, E. J., Jang, H. J., Moon, H. Y., Byun, H. Y., Kim, E. K., Kim, D. H., Lee, M. N., Koh, A., Ghim, J., Choi, J. H., Lee-Kwon, W., Kim, K. T., Ryu, S. H., and Suh, P. G. (2012) O-GlcNAcase is essential for embryonic development and maintenance of genomic stability, *Aging Cell* **11**, 439-448.
- [4] Hanover, J., Keembiyehetty, C., Wang, P., Comly, M., Dwyer, N., Krause, M., and Love, D. (2010) Mouse O-GlcNAcase Knockout Reveals Roles for O-GlcNAc Cycling in Development, Metabolism and Epigenetics, *Glycobiology* **20**, 1453-1453.
- [5] Ranuncolo, S. M., Ghosh, S., Hanover, J. A., Hart, G. W., and Lewis, B. A. (2012) Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo, *J. Biol. Chem.*
- [6] Fujiki, R., Hashiba, W., Sekine, H., Yokoyama, A., Chikanishi, T., Ito, S., Imai, Y., Kim, J., He, H. H., Igarashi, K., Kanno, J., Ohtake, F., Kitagawa, H., Roeder, R. G., Brown, M., and Kato, S. (2011) GlcNAcylation of histone H2B facilitates its monoubiquitination, *Nature* **480**, 557-U188.
- [7] Chen, Q., Chen, Y., Bian, C., Fujiki, R., and Yu, X. (2013) TET2 promotes histone O-GlcNAcylation during gene transcription, *Nature* **493**, 561-564.
- [8] Deplus, R., Delatte, B., Schwinn, M. K., Defrance, M., Mendez, J., Murphy, N., Dawson, M. A., Volkmar, M., Putmans, P., Calonne, E., Shih, A. H., Levine, R. L., Bernard, O., Mercher, T., Solary, E., Urh, M., Daniels, D. L., and Fuks, F. (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS, *EMBO J.* **32**, 645-655.
- [9] Yang, W. H., Park, S. Y., Nam, H. W., Kim do, H., Kang, J. G., Kang, E. S., Kim, Y. S., Lee, H. C., Kim, K. S., and Cho, J. W. (2008) NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions, *Proc. Natl. Acad. Sci. U. S. A.* **105**, 17345-17350.
- [10] Zachara, N. E., and Hart, G. W. (2004) O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress, *Biochim. Biophys. Acta* **1673**, 13-28.
- [11] Zachara, N. E., O'Donnell, N., Cheung, W. D., Mercer, J. J., Marth, J. D., and Hart, G. W. (2004) Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress - A survival response of mammalian cells, *Journal of Biological Chemistry* **279**, 30133-30142.
- [12] Liu, J., Pang, Y., Chang, T., Bounelis, P., Chatham, J. C., and Marchase, R. B. (2006) Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia, *Journal of Molecular and Cellular Cardiology* **40**, 303-312.
- [13] Erickson, J. R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., Copeland, R. J., Despa, F., Hart, G. W., Ripplinger, C. M., and Bers, D. M. (2013) Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation, *Nature* **502**, 372-376.
- [14] Marsh, S. A., Powell, P. C., Dell'Italia, L. J., and Chatham, J. C. (2013) Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart, *Life Sciences* **92**, 648-656.
- [15] Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Vocadlo, D. J., Liu, F., and Gong, C. X. (2012) Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation, *PLoS ONE* **7**, e35277.
- [16] Schimpl, M., Borodkin, V. S., Gray, L. J., and van Aalten, D. M. (2012) Synergy of peptide and sugar in O-GlcNAcase substrate recognition, *Chem Biol* **19**, 173-178.

- [17] Schimpl, M., Schuttelkopf, A. W., Borodkin, V. S., and van Aalten, D. M. (2010) Human OGA binds substrates in a conserved peptide recognition groove, *Biochem J* 432, 1-7.
- [18] Li, B., Li, H., Lu, L., and Jiang, J. (2017) Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode, *Nat Struct Mol Biol* 24, 362-369.
- [19] Roth, C., Chan, S., Offen, W. A., Hemsworth, G. R., Willems, L. I., King, D. T., Varghese, V., Britton, R., Vocadlo, D. J., and Davies, G. J. Structural and functional insight into human O-GlcNAcase.
- [20] Elsen, N. L., Patel, S. B., Ford, R. E., Hall, D. L., Hess, F., Kandula, H., Kornienko, M., Reid, J., Selnick, H., Shipman, J. M., Sharma, S., Lumb, K. J., Soisson, S. M., and Klein, D. J. (2017) Insights into activity and inhibition from the crystal structure of human O-GlcNAcase, *Nat Chem Biol*.
- [21] Lazarus, M. B., Nam, Y., Jiang, J., Sliz, P., and Walker, S. (2011) Structure of human O-GlcNAc transferase and its complex with a peptide substrate, *Nature* 469, 564-567.
- [22] Lazarus, M. B., Jiang, J., Gloster, T. M., Zandberg, W. F., Whitworth, G. E., Vocadlo, D. J., and Walker, S. (2012) Structural snapshots of the reaction coordinate for O-GlcNAc transferase, *Nat. Chem. Biol.* 8, 966-968.
- [23] Schimpl, M., Zheng, X., Borodkin, V. S., Blair, D. E., Ferenbach, A. T., Schuttelkopf, A. W., Navratilova, I., Aristotelous, T., Albarbarawi, O., Robinson, D. A., Macnaughtan, M. A., and van Aalten, D. M. (2012) O-GlcNAc transferase invokes nucleotide sugar pyrophosphate participation in catalysis, *Nat. Chem. Biol.* 8, 969-974.
- [24] Rao, F. V., Dorfmüller, H. C., Villa, F., Allwood, M., Eggleston, I. M., and van Aalten, D. M. (2006) Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis, *EMBO J.* 25, 1569-1578.
- [25] Dennis, R. J., Taylor, E. J., Macauley, M. S., Stubbs, K. A., Turkenburg, J. P., Hart, S. J., Black, G. N., Vocadlo, D. J., and Davies, G. J. (2006) Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity, *Nature Structural & Molecular Biology* 13, 365-371.
- [26] Gross, B. J., Kraybill, B. C., and Walker, S. (2005) Discovery of O-GlcNAc transferase inhibitors, *J Am Chem Soc* 127, 14588-14589.
- [27] Gloster, T. M., Zandberg, W. F., Heinonen, J. E., Shen, D. L., Deng, L., and Vocadlo, D. J. (2011) Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells, *Nat. Chem. Biol.* 7, 174-181.
- [28] Borodkin, V. S., Schimpl, M., Gundogdu, M., Rafie, K., Dorfmüller, H. C., Robinson, D. A., and van Aalten, D. M. (2014) Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase inhibitors, *Biochem J* 457, 497-502.
- [29] Macauley, M. S., Whitworth, G. E., Debowski, A. W., Chin, D., and Vocadlo, D. J. (2005) O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors, *J. Biol. Chem.* 280, 25313-25322.
- [30] Macauley, M. S., Shan, X., Yuzwa, S. A., Gloster, T. M., and Vocadlo, D. J. (2010) Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis (vol 17, pg 949, 2010), *Chem. Biol.* 17, 1161-1161.
- [31] Dorfmüller, H. C., Borodkin, V. S., Schimpl, M., Shepherd, S. M., Shpiro, N. A., and van Aalten, D. M. F. (2006) GlcNAcstatin: A picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels, *J Am Chem Soc* 128, 16484-16485.
- [32] Dorfmüller, H. C., Borodkin, V. S., Schimpl, M., and van Aalten, D. M. (2009) GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation, *Biochem. J.* 420, 221-227.
- [33] Dorfmüller, H. C., Borodkin, V. S., Schimpl, M., Zheng, X., Kime, R., Read, K. D., and van Aalten, D. M. (2010) Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases, *Chem. Biol.* 17, 1250-1255.
- [34] Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., and Vocadlo, D. J. (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation, *Nat. Chem. Biol.* 8, 393-399.

- 1 [35] Kim, C., Nam, D. W., Park, S. Y., Song, H., Hong, H. S., Boo, J. H., Jung, E. S., Kim, Y., Baek, J. Y., Kim, K. S.,
2 Cho, J. W., and Mook-Jung, I. (2013) O-linked beta-N-acetylglucosaminidase inhibitor attenuates
3 beta-amyloid plaque and rescues memory impairment, *Neurobiol. Aging* 34, 275-285.
- 4 [36] Laczy, B., Marsh, S. A., Brocks, C. A., Wittmann, I., and Chatham, J. C. (2010) Inhibition of O-GlcNAcase
5 in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-
6 GlcNAc-dependent manner, *Am. J. Physiol. Heart Circ. Physiol.* 299, H1715-1727.
- 7 [37] Champattanachai, V., Marchase, R. B., and Chatham, J. C. (2008) Glucosamine protects neonatal
8 cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased
9 mitochondrial Bcl-2, *Am. J. Physiol. Cell Physiol.* 294, C1509-1520.
- 10 [38] Li, T., Guo, L., Zhang, Y., Wang, J., Li, Z., Lin, L., Zhang, Z., Li, L., Lin, J., Zhao, W., Li, J., and Wang, P. G.
11 (2011) Design and synthesis of O-GlcNAcase inhibitors via 'click chemistry' and biological
12 evaluations, *Carbohydr. Res.* 346, 1083-1092.
- 13 [39] Dorfmueller, H. C., and van Aalten, D. M. F. (2010) Screening-based discovery of drug-like O-
14 GlcNAcase inhibitor scaffolds, *Febs Letters* 584, 694-700.
- 15 [40] Rossi, A. M., and Taylor, C. W. (2011) Analysis of protein-ligand interactions by fluorescence
16 polarization, *Nat. Protocols* 6, 365-387.
- 17 [41] Peterson, K. J., Sadowsky, J. D., Scheef, E. A., Pal, S., Kourentzi, K. D., Willson, R. C., Bresnick, E. H.,
18 Sheibani, N., and Gellman, S. H. (2008) A fluorescence polarization assay for identifying ligands
19 that bind to vascular endothelial growth factor, *Analytical Biochemistry* 378, 8-14.
- 20 [42] (1981) Isolation and further characterization of bovine brain hexosaminidase C, *Biochimica et*
21 *Biophysica Acta (BBA) - Enzymology* 659, 255 - 266.
- 22 [43] Borodkin, V. S., and van Aalten, D. M. F. (2010) An efficient and versatile synthesis of GlcNAcstatins-
23 potent and selective O-GlcNAcase inhibitors built on the tetrahydroimidazo[1,2-a]pyridine
24 scaffold, *Tetrahedron* 66, 7838-7849.
- 25 [44] Zolle, I. M., Berger, M. L., Hammerschmidt, F., Hahner, S., Schirbel, A., and Peric-Simov, B. (2008) New
26 selective inhibitors of steroid 11 beta-hydroxylation in the adrenal cortex. Synthesis and
27 structure-activity relationship of potent Etomidate analogues, *J Med Chem* 51, 2244-2253.
- 28 [45] Laha, J. K., and Cuny, G. D. (2011) Synthesis of Fused Imidazoles, Pyrroles, and Indoles with a Defined
29 Stereocenter alpha to Nitrogen Utilizing Mitsunobu Alkylation Followed by Palladium-Catalyzed
30 Cyclization, *J Org Chem* 76, 8477-8482.
- 31 [46] Guianvarc'h, D., Fourrey, J. L., Dau, M., Guerineau, V., and Benhida, R. (2002) Stereocontrolled
32 synthesis of heterocyclic C-nucleosides. Protecting group effect and molecular modeling studies, *J*
33 *Org Chem* 67, 3724-3732.
- 34 [47] Yokoyama, M., Tanabe, T., Toyoshima, A., and Togo, H. (1993) SYNTHESIS OF C-NUCLEOSIDES
35 HAVING TYPICAL AROMATIC HETEROCYCLES AS THE BASE MOIETY, *Synthesis-Stuttgart*, 517-
36 520.
- 37 [48] Yan, L., and Kahne, D. (1995) P-Methoxybenzyl Ethers as Acid-Labile Protecting Groups in
38 Oligosaccharide Synthesis, *Synlett*, 523-524.
- 39 [49] Hense, A., Ley, S. V., Osborn, H. M. I., Owen, D. R., Poisson, J. F., Warriner, S. L., and Wesson, K. E.
40 (1997) Direct preparation of diacetals from 1,2-diketones and their use as 1,2-diol protecting
41 groups, *J Chem Soc Perk T 1*, 2023-2031.
- 42 [50] Corey, E. J., Li, W. D., and Reichard, G. A. (1998) A new magnesium-catalyzed doubly
43 diastereoselective anti-aldol reaction leads to a highly efficient process for the total synthesis of
44 lactacystin in quantity, *J Am Chem Soc* 120, 2330-2336.
- 45 [51] Palladino, P., and Stetsenko, D. A. (2012) New TFA-Free Cleavage and Final Deprotection in Fmoc
46 Solid-Phase Peptide Synthesis: Dilute HCl in Fluoro Alcohol, *Org Lett* 14, 6346-6349.
- 47 [52] Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., Zheng, X., Kime, R., Read, K. D., and van Aalten, D. M.
48 (2010) Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal
49 hexosaminidases, *Chem Biol* 17, 1250-1255.
- 50
51
52
53
54
55
56
57
58
59
60

- 1 [53] Tropak, M. B., Blanchard, J. E., Withers, S. G., Brown, E. D., and Mahuran, D. (2007) High-throughput
2 screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as
3 pharmacological chaperones, *Chem. Biol.* *14*, 153-164.
- 4 [54] Kabsch, W. (2010) Xds, *Acta Crystallogr D Biol Crystallogr* *66*, 125-132.
- 5 [55] Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel,
6 E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A.,
7 Powell, H. R., Read, R. J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current
8 developments, *Acta Crystallogr D Biol Crystallogr* *67*, 235-242.
- 9 [56] Vagin, A., and Teplyakov, A. (2010) Molecular replacement with MOLREP, *Acta Crystallographica*
10 *Section D* *66*, 22-25.
- 11 [57] <Murshudov, Vagin, Dodson - 1997 - Refinement of macromolecular structures by the maximum-
12 likelihood method.pdf>.
- 13 [58] Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot, *Acta*
14 *Crystallogr D Biol Crystallogr* *66*, 486-501.
- 15 [59] Schuttelkopf, A. W., and van Aalten, D. M. F. (2004) PRODRG: a tool for high-throughput
16 crystallography of protein-ligand complexes, *Acta Crystallographica Section D* *60*, 1355-1363.
- 17 [60] Nikolovska-Coleska, Z., Wang, R., Fang, X., Pan, H., Tomita, Y., Li, P., Roller, P. P., Krajewski, K., Saito, N.
18 G., Stuckey, J. A., and Wang, S. (2004) Development and optimization of a binding assay for the
19 XIAP BIR3 domain using fluorescence polarization, *Anal. Biochem.* *332*, 261-273.
- 20 [61] Berman, H. M. a. W. J. a. F. Z. a. G. G. a. B. T. N. a. W. H. a. S. I. N. a. B. P. E. (2000) The Protein Data
21 Bank, *Nucleic Acids Research* *28*, 235-242.
- 22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



High affinity fluorescent tracer



Highthroughput OGA



OGA inhibitors

Fluorescent Polarization Assay

ACS Paragon Plus Environment